Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy
Journal of Controlled Release · 2023-10 · 362 · 479-488
DOI: 10.1016/j.jconrel.2023.08.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-10. Verfasst von Huajian Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory o…. Hauptthemen laut MEDLINE: Glioblastoma, Doxorubicin, Brain Neoplasms, Neutrophils. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Surgical resection of glioblastoma (GBM) causes brain inflammation that activates and recruits neutrophils (NEs) to residual GBM tissues. NE-based drug delivery using inflammatory chemotaxis is promising for the post-surgical treatment of residual GBM, but its clinical application is limited by the short life span of NEs and lack of in vitro propagation methods. HL60 cells are a type of infinitely multiplying tumor cells that can be induced to differentiate into NE-like cells. We developed a novel NE-like membrane system (NM-PD) by coating NE-like membranes on the surface of poly (lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG)-based doxorubicin (DOX)-loaded core (PLGA-PEG-DOX, PD) for post-surgical residual GBM treatment. Cell adhesion proteins were detected on NE-like membranes and endowed NM-PDs with inflammatory chemotaxis similar to mature NEs. The resulting NM-PD shows excellent inflamed in vitro blood-brain barrier (BBB) permeability and anti-proliferative effects on GBM cells. In our intracranial GBM resection model, NM-PD exhibited superior inflammatory chemotaxis and targeted residual GBM cells, thus remarkably improving antitumor capability and prolonging the survival time of the mice. These data suggest that NM-PD, which has sufficient sources and is easy to prepare, can efficiently suppress post-surgical residual GBM and holds potential for clinical transformation in GBM post-surgical adjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery,…
- Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Förderung
- China Postdoctoral Science Foundation
- Guangzhou Municipal Science and Technology Project
- National Natural Science Foundation of China
Zitieren
APA
Chen, H., Ji, J., Zhang, L., Chen, T., Zhang, Y., Zhang, F., Wang, J., & Ke, Y. (2023). Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy. Journal of Controlled Release, 362, 479-488. https://doi.org/10.1016/j.jconrel.2023.08.020
Vancouver
Chen H, Ji J, Zhang L, Chen T, Zhang Y, Zhang F, et al. Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy. Journal of Controlled Release. 2023;362:479-488. doi:10.1016/j.jconrel.2023.08.020
BibTeX
@article{Chen2023,
author = {Chen, Huajian and Ji, Jingsen and Zhang, Li and Chen, Taoliang and Zhang, Yuxuan and Zhang, Fabing and Wang, Jihui and Ke, Yiquan},
title = {Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy},
journal = {Journal of Controlled Release},
year = {2023},
volume = {362},
pages = {479--488},
doi = {10.1016/j.jconrel.2023.08.020}
}
EUVIMED